Table 4. The cost-effectiveness of 12- and 24-month HPV testing, compared to 12-month HPV testing only, in women with OHR HPV and cytology ASC-US/LSIL.

	Incremental cost-effectiveness ratio (ICER) of 12- and 24-month follow-up compared to 12-month follow-up only (A$/ LYS)
	Unvaccinated cohorts	Cohorts offered vaccination
12 and 24m follow-up for all ages*	$ 238,000	$228,000
12m follow-up for women aged less than 35, then 12 and 24m follow-up for women aged 35+	$147,000	$143,000
12m follow-up for women aged less than 45, then 12 and 24m follow-up for women aged 45+	$97,000	$ 94,000
12m follow-up for women aged less than 55, then 12 and 24m follow-up for women aged 55+	$72,000	$71,000
12m follow-up for women aged less than 65, then 12 and 24m follow-up for women aged 65+	Extended dominated	Extended dominated

LYS = life-years saved.

*The ICER for immediate colposcopy for all ages was calculated compared to 12-month follow-up for all ages. If the ICER was instead compared to immediate colposcopy for women aged 35+ years (which was the next most effective strategy), then the calculated ICER increased, and was >$300,000/LYS for both unvaccinated cohorts and cohort offered vaccination.

Extended dominated = the strategy has a higher ICER than a more effective strategy.